Toceranib phosphate in the management of canine insulinoma: A retrospective multicentre study of 30 cases (2009-2019).
Journal
Veterinary record open
ISSN: 2052-6113
Titre abrégé: Vet Rec Open
Pays: United States
ID NLM: 101653671
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
06
05
2021
revised:
28
09
2021
accepted:
22
11
2021
entrez:
26
1
2022
pubmed:
27
1
2022
medline:
27
1
2022
Statut:
epublish
Résumé
Insulinomas are the most common tumour of the endocrine pancreas in dogs. These malignant tumours have a high metastatic rate and limited chemotherapeutic options. The multi-receptor tyrosine kinase inhibitor sunitinib malate has benefit in the treatment of metastatic insulinoma in people. Toceranib phosphate, an analogous veterinary agent, may provide benefit for dogs. A retrospective study describing the extent and duration of clinical outcomes and adverse events (AEs) in dogs diagnosed with insulinoma and receiving toceranib. Records for 30 dogs diagnosed with insulinoma and having received toceranib were identified from a medical record search of five university and eight referral hospitals. The median progression-free interval and overall survival time were 561 days (95% confidence interval (CI): [246, 727 days]) and 656 days (95% CI: [310, 1045 days]), respectively. Of the dogs for which the canine Response evaluation criteria for solid tumours tool could be applied, the majority (66.7%) showed either a complete response, partial response or stable disease. Time to clinical progression was associated with prior intervention and type of veterinary practice. Larger dogs were at increased risk for disease progression and death. No novel AEs were reported. Most dogs diagnosed with insulinoma and receiving toceranib appeared to have a clinical benefit. Randomised, prospective studies are needed to better elucidate and objectively quantify the potential effect and survival benefit of toceranib therapy for management of insulinoma in dogs.
Sections du résumé
BACKGROUND
BACKGROUND
Insulinomas are the most common tumour of the endocrine pancreas in dogs. These malignant tumours have a high metastatic rate and limited chemotherapeutic options. The multi-receptor tyrosine kinase inhibitor sunitinib malate has benefit in the treatment of metastatic insulinoma in people. Toceranib phosphate, an analogous veterinary agent, may provide benefit for dogs.
METHODS
METHODS
A retrospective study describing the extent and duration of clinical outcomes and adverse events (AEs) in dogs diagnosed with insulinoma and receiving toceranib.
RESULTS
RESULTS
Records for 30 dogs diagnosed with insulinoma and having received toceranib were identified from a medical record search of five university and eight referral hospitals. The median progression-free interval and overall survival time were 561 days (95% confidence interval (CI): [246, 727 days]) and 656 days (95% CI: [310, 1045 days]), respectively. Of the dogs for which the canine Response evaluation criteria for solid tumours tool could be applied, the majority (66.7%) showed either a complete response, partial response or stable disease. Time to clinical progression was associated with prior intervention and type of veterinary practice. Larger dogs were at increased risk for disease progression and death. No novel AEs were reported.
CONCLUSIONS
CONCLUSIONS
Most dogs diagnosed with insulinoma and receiving toceranib appeared to have a clinical benefit. Randomised, prospective studies are needed to better elucidate and objectively quantify the potential effect and survival benefit of toceranib therapy for management of insulinoma in dogs.
Identifiants
pubmed: 35079406
doi: 10.1002/vro2.27
pii: VRO227
pmc: PMC8776903
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e27Informations de copyright
© 2022 The Authors. Veterinary Record Open published by John Wiley & Sons Ltd on behalf of British Veterinary Association.
Déclaration de conflit d'intérêts
The authors declare they have no conflicts of interest.
Références
BMC Vet Res. 2016 Nov 17;12(1):257
pubmed: 27855679
N Engl J Med. 2011 Feb 10;364(6):501-13
pubmed: 21306237
J Natl Cancer Inst. 2015 Nov 07;108(1):
pubmed: 26547927
Clin Cancer Res. 2007 Mar 1;13(5):1367-73
pubmed: 17332278
J Vet Intern Med. 2018 Nov;32(6):2045-2053
pubmed: 30307656
Ann Endocrinol (Paris). 2018 Oct;79(5):574-582
pubmed: 30174137
Vet J. 2014 Jul;201(1):57-63
pubmed: 24878267
Oncologist. 2012;17(8):1108-13
pubmed: 22836448
J Vet Intern Med. 2020 Mar;34(2):873-881
pubmed: 31977135
J Am Anim Hosp Assoc. 2019 Jan/Feb;55(1):e55105
pubmed: 30427714
Vet J. 2010 Jul;185(1):62-7
pubmed: 20570189
Vet Q. 1998;20 Suppl 1:S114-5
pubmed: 9652051
Leuk Res. 2014 Dec;38(12):1392-8
pubmed: 25449685
J Am Vet Med Assoc. 2019 Apr 15;254(8):960-966
pubmed: 30938616
N Z Vet J. 2021 Jul;69(4):234-239
pubmed: 33944682
Vet Comp Oncol. 2021 Sep;19(3):428-441
pubmed: 32558184
Onco Targets Ther. 2016 Sep 08;9:5495-505
pubmed: 27660467
J Oncol Pharm Pract. 2011 Sep;17(3):197-202
pubmed: 20685771
J Small Anim Pract. 2007 Mar;48(3):151-6
pubmed: 17355606
J Vet Med Sci. 2009 Jul;71(7):905-11
pubmed: 19652477
J Am Vet Med Assoc. 1986 Jan 1;188(1):60-4
pubmed: 3003016
Lancet. 2006 Oct 14;368(9544):1329-38
pubmed: 17046465
Probl Vet Med. 1990 Dec;2(4):602-9
pubmed: 1983699
Clin Cancer Res. 2009 Jun 1;15(11):3856-65
pubmed: 19470739
J Am Anim Hosp Assoc. 2019 Sep/Oct;55(5):243-248
pubmed: 31433219
J Vet Intern Med. 2020 May;34(3):1272-1281
pubmed: 32267594
Clin Cancer Res. 2003 Jul;9(7):2755-68
pubmed: 12855656
BMC Vet Res. 2018 Sep 3;14(1):272
pubmed: 30176869
Vet Comp Oncol. 2019 Dec;17(4):465-471
pubmed: 31069932
Vet Comp Oncol. 2012 Sep;10(3):194-205
pubmed: 22236194
Blood. 2002 Jul 15;100(2):585-93
pubmed: 12091352
N Engl J Med. 2007 Jan 11;356(2):115-24
pubmed: 17215529
J Am Vet Med Assoc. 2002 Sep 15;221(6):811-8
pubmed: 12322919
J Clin Oncol. 2008 Jul 10;26(20):3403-10
pubmed: 18612155
J Small Anim Pract. 1995 Apr;36(4):161-5
pubmed: 7603057
Vet Comp Oncol. 2015 Sep;13(3):176-83
pubmed: 23534501
J Vet Intern Med. 2020 May;34(3):1135-1143
pubmed: 32212400
Vet Comp Oncol. 2016 Dec;14(4):417-446
pubmed: 28530307
Can Vet J. 2020 Jul;61(7):737-742
pubmed: 32655157
J Vet Intern Med. 2013 May-Jun;27(3):483-90
pubmed: 23600734
Vet Comp Oncol. 2020 Dec;18(4):519-527
pubmed: 32012432
Res Vet Sci. 2006 Feb;80(1):25-32
pubmed: 15946716
J Am Vet Med Assoc. 1982 Jul 1;181(1):54-8
pubmed: 6286582
J Am Anim Hosp Assoc. 2018 Nov 14;:
pubmed: 30427710
BMC Vet Res. 2013 Sep 30;9:190
pubmed: 24079884
J Am Anim Hosp Assoc. 2012 May-Jun;48(3):151-63
pubmed: 22474047
J Clin Oncol. 2006 Jan 1;24(1):25-35
pubmed: 16314617
Clin Cancer Res. 2003 Nov 15;9(15):5729-34
pubmed: 14654558
J Am Vet Med Assoc. 1999 Jul 15;215(2):226-30
pubmed: 10416477